ACTBL2

Summary

ACTBL2 (actin beta like 2, HGNC:17780) is a protein-coding gene on chromosome 5q11.2, encoding Beta-actin-like protein 2 (Q562R1). Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.

Predicted to enable protein kinase binding activity. Predicted to be a structural constituent of postsynaptic actin cytoskeleton. Predicted to be involved in axonogenesis and cell motility. Located in extracellular exosome.

Source: NCBI Gene 345651 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 77 total — 3 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_001017992

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17780
Approved symbol	ACTBL2
Name	actin beta like 2
Location	5q11.2
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp686D0972
Ensembl gene	ENSG00000169067
Ensembl biotype	protein_coding
OMIM	614835
Entrez	345651

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000423391

RefSeq mRNA: 1 — MANE Select: NM_001017992 NM_001017992

CCDS: CCDS34163

Canonical transcript exons

ENST00000423391 — 1 exons

Exon	Start	End
ENSE00001649584	57480018	57482811

Expression profiles

Bgee: expression breadth broad, 24 present calls, max score 49.52.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3435 / max 18.5201, expressed in 139 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
61764	0.2800	113
61763	0.0635	32

Top tissues by expression

120 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	49.52	gold quality
islet of Langerhans	UBERON:0000006	45.95	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	43.81	gold quality
placenta	UBERON:0001987	41.47	gold quality
gastrocnemius	UBERON:0001388	41.45	silver quality
ganglionic eminence	UBERON:0004023	40.71	gold quality
muscle of leg	UBERON:0001383	40.58	silver quality
skeletal muscle tissue	UBERON:0001134	40.43	gold quality
hindlimb stylopod muscle	UBERON:0004252	38.72	gold quality
muscle tissue	UBERON:0002385	38.40	gold quality
vermiform appendix	UBERON:0001154	38.00	gold quality
colonic epithelium	UBERON:0000397	37.20	gold quality
minor salivary gland	UBERON:0001830	36.93	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
saliva-secreting gland	UBERON:0001044	36.23	gold quality
bone marrow cell	CL:0002092	36.16	gold quality
granulocyte	CL:0000094	36.13	gold quality
apex of heart	UBERON:0002098	34.92	gold quality
pancreas	UBERON:0001264	34.05	gold quality
tonsil	UBERON:0002372	33.62	gold quality
smooth muscle tissue	UBERON:0001135	32.42	gold quality
descending thoracic aorta	UBERON:0002345	32.26	gold quality
bone marrow	UBERON:0002371	31.74	gold quality
liver	UBERON:0002107	31.37	gold quality
left uterine tube	UBERON:0001303	31.03	gold quality
sural nerve	UBERON:0015488	30.93	gold quality
gall bladder	UBERON:0002110	30.90	gold quality
tibial artery	UBERON:0007610	30.64	gold quality
popliteal artery	UBERON:0002250	30.62	gold quality
skin of abdomen	UBERON:0001416	30.48	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	2.79

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): KDM5B

miRNA regulators (miRDB)

73 targeting ACTBL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-944	99.82	70.85	3042

Literature-anchored findings (GeneRIF, showing 5)

• -actin is downregulated in the corneal stroma of patients with KC, which may be related to reduced levels of a stabilizing factor (HuR) for beta-actin mRNA. (PMID:22562506)
• Four rare missense variants were identified (ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), KRT13 rs150321809 (17q21.2) and MC2R rs104894658 (18p11.21)), but only MC2R rs104894668 had a large effect size (OR = 9.66). (PMID:27378695)
• identified a novel protein, ACTBL2, which was demonstrated to be upregulated in colorectal cancer (PMID:27989943)
• The origin of the expressed retrotransposed gene ACTBL2 and its influence on human melanoma cells’ motility and focal adhesion formation. (PMID:33558623)
• Characterization and prognostic impact of ACTBL2-positive tumor-infiltrating leukocytes in epithelial ovarian cancer. (PMID:38114558)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Actbl2	ENSMUSG00000055194
rattus_norvegicus	Actbl2	ENSRNOG00000043292

Paralogs (26): ACTR6 (ENSG00000075089), ACTB (ENSG00000075624), ACTL6B (ENSG00000077080), ACTR5 (ENSG00000101442), ACTR3C (ENSG00000106526), ACTA2 (ENSG00000107796), ACTR8 (ENSG00000113812), ACTR1B (ENSG00000115073), ACTR3 (ENSG00000115091), ACTL8 (ENSG00000117148), ACTRT1 (ENSG00000123165), ACTR10 (ENSG00000131966), ACTR3B (ENSG00000133627), ACTL6A (ENSG00000136518), ACTR2 (ENSG00000138071), ACTR1A (ENSG00000138107), ACTA1 (ENSG00000143632), ACTL7B (ENSG00000148156), ACTC1 (ENSG00000159251), ACTG2 (ENSG00000163017), ACTRT2 (ENSG00000169717), ACTL9 (ENSG00000181786), ACTG1 (ENSG00000184009), ACTRT3 (ENSG00000184378), ACTL7A (ENSG00000187003), ACTL10 (ENSG00000288649)

Protein

Protein identifiers

Beta-actin-like protein 2 — Q562R1 (reviewed: Q562R1)

Alternative names: Kappa-actin

All UniProt accessions (1): Q562R1

UniProt curated annotations — full annotation on UniProt →

Function. Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.

Subunit / interactions. Polymerization of globular actin (G-actin) leads to a structural filament (F-actin) in the form of a two-stranded helix. Each actin can bind to 4 others. Interacts with PFN1 and PFDN1.

Subcellular location. Cytoplasm. Cytoskeleton.

Post-translational modifications. Oxidation of Met-45 and Met-48 by MICALs (MICAL1, MICAL2 or MICAL3) to form methionine sulfoxide promotes actin filament depolymerization. MICAL1 and MICAL2 produce the (R)-S-oxide form. The (R)-S-oxide form is reverted by MSRB1 and MSRB2, which promote actin repolymerization. Monomethylation at Lys-85 (K84me1) regulates actin-myosin interaction and actomyosin-dependent processes. Demethylation by ALKBH4 is required for maintaining actomyosin dynamics supporting normal cleavage furrow ingression during cytokinesis and cell migration.

Miscellaneous. In vertebrates 3 main groups of actin isoforms, alpha, beta and gamma have been identified. The alpha actins are found in muscle tissues and are a major constituent of the contractile apparatus. The beta and gamma actins coexist in most cell types as components of the cytoskeleton and as mediators of internal cell motility.

Similarity. Belongs to the actin family.

RefSeq proteins (1): NP_001017992* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004000	Actin	Family
IPR004001	Actin_CS	Conserved_site
IPR020902	Actin/actin-like_CS	Conserved_site
IPR043129	ATPase_NBD	Homologous_superfamily

Pfam: PF00022

UniProt features (7 total): sequence conflict 4, modified residue 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q562R1-F1	94.97	0.92

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 45, 48

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 63 (showing top): GOBP_NEUROGENESIS, GOBP_CELL_JUNCTION_ORGANIZATION, GOCC_NEURON_PROJECTION, GOBP_CELL_PROJECTION_ORGANIZATION, GOCC_H4_HISTONE_ACETYLTRANSFERASE_COMPLEX, GOCC_TRANSFERASE_COMPLEX, chr5q11, GOCC_SYNAPSE, MARSON_BOUND_BY_FOXP3_STIMULATED, GOCC_AXON, GOMF_KINASE_BINDING, GOMF_STRUCTURAL_CONSTITUENT_OF_CYTOSKELETON, GOMF_ADENYL_NUCLEOTIDE_BINDING, GOMF_STRUCTURAL_MOLECULE_ACTIVITY, CHEN_METABOLIC_SYNDROM_NETWORK

GO Biological Process (3): axonogenesis (GO:0007409), cell motility (GO:0048870), postsynaptic actin cytoskeleton organization (GO:0098974)

GO Molecular Function (5): ATP binding (GO:0005524), protein kinase binding (GO:0019901), structural constituent of postsynaptic actin cytoskeleton (GO:0098973), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (11): obsolete extracellular space (GO:0005615), cytoplasm (GO:0005737), actin filament (GO:0005884), actin cytoskeleton (GO:0015629), membrane (GO:0016020), axon (GO:0030424), NuA4 histone acetyltransferase complex (GO:0035267), extracellular exosome (GO:0070062), glutamatergic synapse (GO:0098978), cytoskeleton (GO:0005856), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cell morphogenesis involved in neuron differentiation	1
neuron projection morphogenesis	1
axon development	1
cellular process	1
actin cytoskeleton organization	1
postsynaptic cytoskeleton organization	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
kinase binding	1
structural constituent of cytoskeleton	1
postsynaptic actin cytoskeleton	1
postsynaptic actin cytoskeleton organization	1
structural constituent of postsynapse	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
intracellular anatomical structure	1
actin cytoskeleton	1
polymeric cytoskeletal fiber	1
cytoskeleton	1
neuron projection	1
H4/H2A histone acetyltransferase complex	1
extracellular vesicle	1
synapse	1
intracellular membraneless organelle	1
cell junction	1

Protein interactions and networks

STRING

2476 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ACTBL2	PFDN2	Q9UHV9	888
ACTBL2	PFDN1	O60925	786
ACTBL2	PFN1	P07737	580
ACTBL2	GSN	P06396	569
ACTBL2	SCIN	Q9Y6U3	525
ACTBL2	TUBB6	Q9BUF5	494
ACTBL2	PRDX2	P31945	491
ACTBL2	TUBB3	Q13509	461
ACTBL2	ENO2	P09104	435
ACTBL2	PRPF40A	O75400	431
ACTBL2	RAB3GAP1	Q15042	418
ACTBL2	CASKIN1	Q8WXD9	410
ACTBL2	MIF	P14174	403
ACTBL2	ANP32B	P78458	401
ACTBL2	POTEB2	H3BUK9	395

IntAct

333 interactions, top by confidence:

A	B	Type	Score
CEP97	CCP110	psi-mi:“MI:0914”(association)	0.950
RAD21	SMC1A	psi-mi:“MI:0914”(association)	0.930
WASL	WIPF3	psi-mi:“MI:0914”(association)	0.740
HOMER1	TRAF5	psi-mi:“MI:0914”(association)	0.740
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
UQCRB	COX7A2L	psi-mi:“MI:0914”(association)	0.640
RNASE3	GGPS1	psi-mi:“MI:0914”(association)	0.640
CFL1	CAP2	psi-mi:“MI:0914”(association)	0.640
TWF2	CAP2	psi-mi:“MI:0914”(association)	0.640
MAPK7	PFDN6	psi-mi:“MI:0914”(association)	0.640
CEP97	ACTBL2	psi-mi:“MI:0915”(physical association)	0.610
SRD5A1	ACTBL2	psi-mi:“MI:0915”(physical association)	0.590
ADA	POTEF	psi-mi:“MI:0914”(association)	0.560
HTR1E	ATP5F1B	psi-mi:“MI:0914”(association)	0.560
GC	POTEF	psi-mi:“MI:0914”(association)	0.530
MAGEA10	POTEF	psi-mi:“MI:0914”(association)	0.530
ACTBL2	POTEF	psi-mi:“MI:0914”(association)	0.530
LPGAT1	POTEF	psi-mi:“MI:0914”(association)	0.530
GPR141	STXBP3	psi-mi:“MI:0914”(association)	0.530
DEFB127	DCTN6	psi-mi:“MI:0914”(association)	0.530
TEX264	PER1	psi-mi:“MI:0914”(association)	0.530
DUSP19	NARS1	psi-mi:“MI:0914”(association)	0.530
DEFA6	EXTL3	psi-mi:“MI:0914”(association)	0.530
CYP1A1	SNX3	psi-mi:“MI:0914”(association)	0.530
ZMAT5	DENND4B	psi-mi:“MI:0914”(association)	0.530
FBXO40	MYO1D	psi-mi:“MI:0914”(association)	0.530
ZNF517	GGPS1	psi-mi:“MI:0914”(association)	0.530
CAPNS2	CAPNS1	psi-mi:“MI:0914”(association)	0.530

BioGRID (468): ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Proximity Label-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS)

ESM2 similar proteins: A5DQP9, O13419, O17502, O17503, O74258, P04751, P10365, P10989, P11426, P12717, P14235, P17128, P18499, P20359, P26183, P30161, P30164, P30165, P43239, P53455, P53457, P53459, P53465, P53466, P53467, P53474, P53491, P60009, P60010, P60011, P62736, P62737, P62738, P62739, P78711, P84856, Q00214, Q00215, Q25472, Q55EU6

Diamond homologs: A0A1L8EV45, A2X6S3, A2XLF2, O00937, O16808, O17320, O73723, O74258, P02576, P02578, P04752, P04829, P07829, P0DM41, P0DM42, P10984, P10986, P10988, P10990, P12432, P12433, P12715, P13363, P14235, P17126, P17128, P20904, P22132, P26183, P30162, P30163, P32390, P32392, P35432, P41112, P41113, P41339, P41341, P42528, P43239

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 272 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
VEGFR2 mediated cell proliferation	5	14.9×	4e-03
Signaling by high-kinase activity BRAF mutants	6	9.9×	5e-03
MAP2K and MAPK activation	6	8.9×	7e-03
Signaling by RAF1 mutants	6	8.7×	7e-03
EPHB-mediated forward signaling	6	8.3×	8e-03
Signaling by moderate kinase activity BRAF mutants	6	7.9×	8e-03
Paradoxical activation of RAF signaling by kinase inactive BRAF	6	7.9×	8e-03
Signaling downstream of RAS mutants	6	7.9×	8e-03

GO biological processes:

GO term	Partners	Fold	FDR
actin polymerization or depolymerization	5	15.2×	6e-03
intrinsic apoptotic signaling pathway	7	10.0×	4e-03
mitophagy	7	8.8×	6e-03
autophagosome assembly	9	8.0×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	1
Uncertain significance	70
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
144590	GRCh38/hg38 5q11.2-12.1(chr5:56947850-61725401)x3	Pathogenic
148227	GRCh38/hg38 5p13.2-q12.1(chr5:35201559-61903141)x3	Pathogenic
57149	GRCh38/hg38 5q11.1-12.1(chr5:50288355-63149770)x1	Pathogenic
3062842	GRCh37/hg19 5q11.1-11.2(chr5:49430268-57925870)x1	Likely pathogenic

SpliceAI

7 predictions. Top by Δscore:

Variant	Effect	Δscore
5:57482677:C:CT	donor_gain	0.6300
5:57482678:T:TT	donor_gain	0.6300
5:57481699:T:TA	donor_gain	0.5000
5:57482676:A:AC	donor_gain	0.3400
5:57481700:C:A	donor_gain	0.3200
5:57481631:A:AC	donor_gain	0.2400
5:57481632:C:CC	donor_gain	0.2400

AlphaMissense

2477 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:57481680:C:T	G343E	0.999
5:57481681:C:A	G343W	0.999
5:57481687:A:G	W341R	0.999
5:57481687:A:T	W341R	0.999
5:57482256:C:T	G151D	0.999
5:57481649:G:C	F353L	0.998
5:57481649:G:T	F353L	0.998
5:57481651:A:G	F353L	0.998
5:57481677:C:T	G344D	0.998
5:57481681:C:G	G343R	0.998
5:57481681:C:T	G343R	0.998
5:57482257:C:G	G151R	0.998
5:57482265:C:G	R148P	0.998
5:57482358:C:G	R117P	0.998
5:57482449:A:G	W87R	0.998
5:57482449:A:T	W87R	0.998
5:57482470:A:G	W80R	0.998
5:57482470:A:T	W80R	0.998
5:57482625:G:T	P28H	0.998
5:57481596:A:T	V371D	0.997
5:57481680:C:A	G343V	0.997
5:57481803:C:T	G302E	0.997
5:57482647:C:G	G21R	0.997
5:57482651:C:A	K19N	0.997
5:57482651:C:G	K19N	0.997
5:57481678:C:G	G344R	0.996
5:57481685:C:A	W341C	0.996
5:57481685:C:G	W341C	0.996
5:57482214:G:T	P165H	0.996
5:57482256:C:A	G151V	0.996

dbSNP variants (sampled 300 via entrez): RS1000719305 (5:57482422 G>A), RS1001005341 (5:57480908 A>G), RS1001096712 (5:57481215 G>A,T), RS1001391486 (5:57483074 G>A,C), RS1003617568 (5:57484690 T>C), RS1004133901 (5:57484429 G>A), RS1004224265 (5:57484659 G>A), RS1004340407 (5:57484415 C>G,T), RS1004561015 (5:57483347 G>A), RS1004672013 (5:57483036 G>A), RS1005506727 (5:57483607 G>A,T), RS1005738281 (5:57479998 A>G), RS1006456409 (5:57479919 A>T), RS1006919706 (5:57480172 A>C,G), RS1007386253 (5:57481347 A>G,T)

Disease associations

OMIM: gene MIM:614835 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST002209_3	Orthostatic hypotension	2.000000e-06
GCST003542_205	Night sleep phenotypes	3.000000e-06
GCST003542_53	Night sleep phenotypes	5.000000e-06
GCST004800_1	Forced expiratory volume in 1 second (environmental tobacco smoke interaction)	4.000000e-06
GCST006530_2	Esophageal adenocarcinoma x smoking interaction	7.000000e-07
GCST006630_66	Diastolic blood pressure	9.000000e-13
GCST007094_185	Diastolic blood pressure	3.000000e-08
GCST008362_220	Birth weight	9.000000e-16
GCST008363_41	Offspring birth weight	2.000000e-06
GCST011205_12	Hypertrophic cardiomyopathy (MTAG)	4.000000e-09
GCST011211_7	Hypertrophic cardiomyopathy	2.000000e-10

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004314	forced expiratory volume
EFO:0008361	environmental tobacco smoke exposure measurement
EFO:0006527	smoking status measurement
EFO:0006336	diastolic blood pressure
EFO:0004344	birth weight
EFO:0005939	parental genotype effect measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, affects cotreatment, affects expression, increases abundance, increases expression	3
sodium arsenite	decreases expression, increases expression	3
Benzo(a)pyrene	increases expression, decreases methylation	2
Estradiol	increases expression, affects expression, affects cotreatment	2
Tobacco Smoke Pollution	affects expression, increases expression	2
sotorasib	affects cotreatment, decreases expression	1
ginger extract	affects cotreatment, affects expression, increases abundance	1
2,4,6-tribromophenol	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, increases expression, affects localization, decreases expression	1
decabromobiphenyl ether	decreases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
tetrabromobisphenol A	decreases expression	1
epigallocatechin gallate	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
trametinib	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Zoledronic Acid	increases expression	1
Benztropine	increases expression	1
Caffeine	increases expression	1
Clozapine	increases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Diethylhexyl Phthalate	increases expression	1
Dopamine	decreases expression	1
Furaldehyde	affects cotreatment, increases expression, affects localization, decreases expression	1
Ivermectin	decreases expression	1
Oils, Volatile	affects expression, increases abundance, affects cotreatment	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.